Platelet adhesion and activation play critical roles in thrombosis and hemostasis. Under high shear rate flow conditions, initial platelet adhesion is mediated by the binding of the platelet von Willebrand Factor (VWF) 1 receptor, the glycoprotein (GP) Ib-IX-V complex, to subendothelial-bound VWF (1, 2) . The GPIb-IX-VWF interaction also initiates an intracellular signaling cascade leading to platelet shape change, spreading, secretion, and aggregation (3) (4) (5) (6) (7) .
The GPIb-IX-V complex is composed of four type I transmembrane polypeptide chains, GPIb␣, GPIb␤, GPIX, and GPV (1, 8) .
GPIb␣ and GPIb␤ are covalently linked through a disulfide bond to form GPIb. GPIX is non-covalently associated with GPIb in a 1:1 ratio, and the GPIb-IX complex is non-covalently associated with GPV in a 2:1 ratio (1, 8) . Expression of the GPV polypeptide is not required for surface expression or the ligandbinding function of the GPIb-IX complex (9) . The extracellular domain of GPIb␣ contains binding sites for VWF and ␣-thrombin (1, 8) . The cytoplasmic domain of GPIb␣ contains binding sites for filamin (also called ABP-280) between residues 536 and 579 (10 -12) , linking the GPIb-IX complex to F-actin structures underlining the plasma membrane. The cytoplasmic domain of GPIb␣ also contains a binding site for the signaling molecule 14-3-3 located between residues 595 and 610 (13, 14) . Phosphorylation of GPIb␣ at Ser 609 is required for high affinity binding of 14-3-3 to GPIb␣ (15). 14-3-3 has been shown to be involved in GPIb-IX-mediated activation of the integrin ␣ IIb ␤ 3 (6) . The cytoplasmic domain of GPIb␤ has been found to interact with calmodulin between residues 149 and 167 (16) . GPIb␤ has also been found to interact with 14-3-3 (17, 18) and is phosphorylated at Ser 166 by PKA (19 -21) . It is known that platelet activation (including VWF-induced platelet activation) is inhibited by compounds that increase the intracellular concentration of cAMP such as prostaglandin E1 (PGE 1 ) and forskolin (6, 22, 23) . Elevation of intracellular cAMP levels induces the activation of PKA. The mechanism by which PKA inhibits platelets is not totally understood but is known to involve phosphorylation of multiple intracellular signaling proteins and regulation of multiple signaling pathways. For example, cAMP has been implicated in inhibiting Ca 2ϩ influx (24) and phospholipase C activation (25) , as well as inhibition of G protein-coupled receptor signaling pathways (26) . One of the major PKA substrates in platelets is GPIb␤ (19 -21) . cAMP-elevating agents have been shown to induce GPIb␤ phosphorylation at Ser 166 (21) . In a study by Fox and Berndt (27) , PKA mediated inhibition of actin polymerization during collagen-induced platelet activation in wild type platelets but not in GPIb-IX-deficient platelets from Bernard-Soulier syndrome patients. This suggests that GPIb-IX and possibly PKA-mediated phosphorylation of GPIb␤ are important in PKA-mediated inhibition of actin polymerization. However, it is not clear if, and how, PKA-mediated GPIb␤ phosphorylation affects GPIb-IX function.
In this study, we have examined the role of phosphorylation of GPIb␤ at Ser 166 in regulating the receptor function of GPIb-IX. We show that wild type GPIb-IX phosphorylated at Ser 166 poorly interacts with VWF. A point mutation that changes Ser 166 of GPIb␤ to alanine disrupts Ser 166 phosphorylation and enhances the VWF-binding function of GPIb-IX. Furthermore, activation of PKA increases GPIb␤ phosphorylation in platelets and inhibits VWF binding to GPIb-IX, whereas inhibition of PKA inhibits GPIb␤ phosphorylation and enhances VWF binding. Thus, PKA-mediated phosphorylation of GPIb␤ at Ser 166 negatively regulates the VWF-binding function of GPIb-IX.
MATERIALS AND METHODS
Reagents-Monoclonal antibodies, SZ29 against VWF and SZ2 against GPIb␣, were generous gifts from Dr. Changgeng Ruan (Suzhou Medical College, Suzhou, China) (28, 29) . cDNA clones encoding wild type GPIb␣, GPIb␤, and GPIX were generous gifts provided by Dr. Jose Lopez (Baylor College of Medicine, Houston, TX) (30 -32) . Human VWF was purified from cryoprecipitates as described previously (33) . Botrocetin was also purified as previously described (34) . Ristocetin, forskolin, and dimethyl sulfoxide (Me 2 SO) were purchased from Sigma. The membrane-permeable PKA inhibitor, myristoylated PKI, was purchased from Calbiochem (San Diego, CA).
Cell Lines Expressing Recombinant Proteins-Transfection of cDNA into CHO cells was performed according to the LipofectAMINE Plus (Invitrogen) protocol. In short, CHO cells were plated at 5.25 ϫ 10 5 cells/60 mm dish then cultured overnight at 37°C in 5% CO 2 . The DNA/LipofectAMINE mixture was added to the CHO cells and incubated for 6 h. at 37°C in 5% CO 2 . Stably transfected cell lines were selected using selection media containing 0.5 mg/ml G418 and further selected by cell sorting using the anti-GPIb␣ monoclonal antibody, SZ2. The following cell lines were used: cells expressing wild type GPIb-IX (1b9) (6); GPIb-IX mutants with the cytoplasmic domain of GPIb␤ truncated at residue 165, lacking amino acids 166 -181 (⌬165); or a serine to alanine point mutation at Ser 166 in GPIb␤ (S166A). For construction of the GPIb␤ mutants ⌬165 and S166A, DNA fragments were synthesized by PCR using wild type GPIb␤ in the pcDNA3.1(Ϫ) vector, as the template. For the construction of the ⌬165 GPIb␤ mutant, the oligonucleotide GGGTCGGTACCTTACACGCGGGCTGCG was used as the reverse primer and CCCTACCGCGACCTGCGTTG was used as the forward primer. These fragments were digested with NotI and KpnI then ligated with GPIb␤ in pcDNA3.1(Ϫ) vector digested with the same enzymes. For the construction of the GPIb␤ S166A mutant, two DNA fragments were synthesized by PCR using the oligonucleotides CCCTACCGCGACCTGCGTTG as the forward and TCAGTGCCAGC-CGGGCTG as the reverse for the 5Ј-fragment and AGCCCGGCTG-GCACTGAC as the forward and TAGAAGGCACAGTCGAGG as the reverse for the 3Ј-fragment using wild type GPIb␤ in the vector pcDNA3.1(Ϫ) as template. The two PCR products (containing a 17-base pair overlap) were combined with the oligonucleotides CCCTACCGC-GACCTGCGTTG as the forward and TAGAAGGCACAGTCGAGG as the reverse and amplified using the following cycling conditions: 94°C ϫ 5 min, 45°C ϫ 1 min, 72°C ϫ 1 min, 94°C ϫ 1 min for 5 cycles followed by 55°C ϫ 1 min, 72°C ϫ 1 min, 94°C ϫ 1 min for 25 cycles, and a final cycle of 55°C ϫ 1 min, 72°C ϫ 5 min. The final product was digested with NotI and KpnI, then ligated with GPIb␤ in pcDNA3.1(Ϫ) vector digested with the same enzymes. The mutant GPIb␤ was sequenced in both the forward and reverse directions to verify the nucleotide sequence.
An Antibody Against the Phosphopeptide Corresponding to the Cytoplasmic Domain of GPIb␤-GPIb␤ peptides, RAAARL(pS)LTDPLV (pS indicates phosphorylated serine) and RAAARLSLTDPLV, containing an N-terminal cysteine were synthesized by Chiron Mimotopes (Melbourne, Australia). The anti-phospho-GPIb␤ (GPIb␤-P) antibody was raised by immunizing New Zealand White rabbits with the phosphorylated CRAAARLpSLTDPLV peptide conjugated to keyhole limpet hemocyanin (Sigma) (35) . The anti-peptide antibody was affinity purified with the immunizing peptide conjugated to BSA and coupled on a 1:1 column of Affi-Gel 10/15 (Bio-Rad). The antibody was then absorbed with the nonphosphorylated CRAAARLSLTDPLV peptide conjugated to BSA, also coupled on a 1:1 column of Affi-Gel 10/15 (Bio-Rad). The specificity of the anti-GPIb␤-P antibody was verified by dot immunoblots against the CRAAARL(pS)LTDPLV and CRAAARLSLTDPLV peptides conjugated to albumin (1:10 w/w). Antibody reactivity was visualized using a horseradish peroxidase-conjugated goat anti-rabbit IgG and enhanced chemiluminescence kit (Amersham Biosciences).
Flow Cytometric Analysis of VWF Binding to GPIb-IX-expressing Cells and Platelets-CHO cells expressing wild type (1b9) and mutant GPIb-IX (⌬165 and S166A) were grown to confluence to synchronize cell growth. The cells were detached using 0.5 mM EDTA in PBS, pH 7.4. Seventy-five percent of the original volume was then resuspended in Dulbecco's modified Eagle's medium growth media and cultured for 18 h. The cells were detached using 0.5 mM EDTA-PBS, pH 7.4, then resuspended in Tyrode's buffer (2.5 mM Hepes, 12.1 mM NaHCO 3 , 2.36 mM KCl, 0.136 M NaCl, 1 mM CaCl 2 , 1 mM MgCl, 0.1% D-glucose, pH 7.4) with 1% BSA to a concentration of 2.25 ϫ 10 6 cells/ml. The cells were incubated at 4°C for 30 min, then ristocetin (1.25 mg/ml) and purified VWF (35 g/ml) were added and incubated at 22°C for 30 min. The cells were washed once with Tyrode's buffer, further incubated in Tyrode's buffer containing 10 g/ml FITC-labeled SZ-29 (monoclonal antibody against VWF) in the dark at 22°C for 30 min and then analyzed by flow cytometry. As negative controls, cells were incubated in the presence of VWF alone or ristocetin alone then incubated with FITC-labeled SZ29. Nonspecific fluorescence was identical for either treatment (data not shown). The 1b9 cells were also preincubated with or without 50 M PKI for 15 min or 2 M forskolin for 5 min at 22°C, prior to analysis for VWF binding.
The preparation of washed platelets was as described previously (36) . Briefly, blood was drawn from healthy donors with no medication within 2 weeks, and anti-coagulated with 1/7 volume of ACD (2.5% trisodium citrate (w/v), 2.0% d-Glucose (w/v), 1.5% citric acid (w/v)). Platelet-rich plasma (PRP) was separated by centrifuging at 300 ϫ g for 25 min. Platelets were washed two times in CGS buffer (0.123 M NaCl, 0.033 M D-Glucose, 0.013 M trisodium citrate, pH 6.5) and were not exposed to cAMP-enhancing agents such as PGE 1 and prostaglandin I 2 (PGI 2 ). The washed platelets were resuspended in modified Tyrode's buffer to a concentration of 1.0 ϫ 10 7 cells/ml and treated with or without 100 M of PKI at 37°C for 15 min. The platelets were further incubated with forskolin (2 M final concentration) or Me 2 SO (0.1% final concentration, vehicle control) at 22°C for 10 min, then incubated with 1 mM RGDS peptide (an integrin inhibitor), 5 g/ml botrocetin, and 35 g/ml VWF at 22°C for 30 min. VWF binding was detected as described above for CHO cells.
Cell Adhesion under Flow-Purified human VWF was diluted to a final concentration of 50 g/ml with 0.1 mM NaHCO 3 , pH 8.3, and coated onto glass cover slides (22 ϫ 40Ϫ1, Fisher) overnight in a humid environment at 4°C. The cover slides were washed with PBS to remove unbound VWF, blocked with 5% BSA in PBS at room temperature for 2 h, and installed in a parallel flow chamber (Model RC-30, Warner Instruments Inc., Hamden, CT) with a silicon rubber gasket. The chamber has a depth of 0.075 mm, a width of 3 mm, and a length of 35 mm. The cells suspended in modified Tyrode's buffer containing 5% bovine serum albumin (5 ϫ 10 6 cells/ml) were perfused by a syringe pump (Harvard Apparatus Inc., Holliston, MA) into the flow chamber at various shear rates for 2 min. Transient adhesion (rolling) of cells on the VWF-coated surface was recorded on video tapes. Shear rate was calculated as described by Slack and Turitto (37) . Transient adherent cells were counted in 10 randomly selected fields of 0.18 mm 2 at randomly selected time points during the perfusion period.
Platelet Agglutination-Whole blood was anti-colaguated with 0.38% sodium citrate, then centrifuged at 350 ϫ g for 25 min and PRP obtained as previously described (38) . The PRP was preincubated with RGDS (1 mM) and PKI (100 M) for 10 min at 22°C or forskolin (2 M) at 22°C for 5 min. VWF-dependent platelet agglutination was induced by the addition of ristocetin (1.25 mg/ml) to the PRP. Platelet agglutination was measured using a turbidometric platelet aggregometer at 37°C with a stirring speed of 1000 rpm.
Immunoprecipitation and Immunodepletion of Phosphorylated GPIb␤-The preparation of washed platelets was as described above (36), and were not exposed to cAMP-enhancing agents such as PGE 1 and PGI 2 . Washed platelets were resuspended in Tyrode's buffer containing 0.1% BSA to a concentration of 1 ϫ 10 9 cells/ml and incubated at 37°C for 30 min. CHO cells expressing wild type Ib-IX (1b9 cells) were detached with 0.5 mM EDTA-PBS, pH 7.4, then resuspended in Tyrode's buffer containing 0.1% BSA to a concentration of 5.0 ϫ 10 7 cells/ml. The cells were solubilized with an equal volume of solubilization buffer (0.1 M Tris, 0.01 M EGTA, 0.15 M NaCl, 2% Triton X-100, pH 7.4) containing 0.2 mM E64 (calpain inhibitor, Roche Molecular Biochemicals), 2 mM phenylmethylsulfonylfluoride (Sigma), and 0.08 units/ml Aprotinin (Sigma) and incubated on ice for 10 min. The lysate was centrifuged at 100,000 ϫ g for 30 min at 4°C. The supernatant (100 l) was incubated with rabbit IgG or purified anti-GPIb␤-P antibody (5 g) at 4°C for 30 min then further incubated for 30 min after the addition of 25 l (50% v/v) of Protein A-conjugated Sepharose beads (Amersham Biosciences). The beads were separated from the supernatant by centrifugation. To quantitate the unphosphorylated GPIb␤ in the platelet lysate, the phosphorylated GPIb␤ was depleted by repeated immunoprecipitation with anti-GPIb␤-P antibody. The immunoprecipitates were combined then washed three times with wash buffer (0.1 M Tris, pH 7.4, 0.15 M NaCl, 10 mM EGTA, 1% Triton X-100). Both the platelet lysates depleted of phosphorylated GPIb␤ and immunoprecipitates were diluted to an identical final volume with SDS sample buffer containing 5% ␤-mercaptoethanol and Western blotted with anti-GPIb␣ antibody, SZ2, to detect the GPIb-IX containing unphosphorylated GPIb␤. The results were visualized with enhanced chemiluminescence (Amersham Biosciences).
RESULTS

Phosphorylation-deficient Mutants of GPIb␤-
To investigate the roles of phosphorylation of GPIb␤ in regulating the functions of GPIb-IX, a conserved point mutation was made in GPIb␤ that replaces Ser 166 with alanine ( Fig. 1) . A truncation mutation was also made that deleted the C-terminal 16 residues of GPIb␤ including Ser 166 . This deletion includes the reported 14-3-3 binding site in GPIb␤ (Fig. 1) . Each of these mutants was co-transfected with GPIb␣ and GPIX cDNAs into CHO cells, and stable cell lines expressing these GPIb-IX mutants were established.
An Anti-GPIb␤ Antibody Specifically Recognizes Phosphorylated Ser 166 -To determine whether the above mentioned mutations abolished Ser 166 phosphorylation in GPIb-IX, and to investigate the phosphorylation of Ser 166 in regulating GPIb-IX function, an anti-peptide antibody was developed using a synthetic peptide corresponding to the RAAARL(pS)LTDPLV sequence of the cytoplasmic domain of GPIb␤ with Ser 166 phosphorylated. This antibody (anti-GPIb␤-P) reacted specifically with the phosphorylated peptide RAAARL(pS)LTDPLV but did not react with the corresponding non-phosphorylated peptide RAAARLSLTDPLV ( Fig. 2A) , indicating the anti-GPIb␤-P antibody recognizes the GPIb␤ cytoplasmic domain sequence only when Ser 166 is phosphorylated. To examine whether antiGPIb␤-P specifically recognizes phosphorylated GPIb␤ in platelets, platelets were solubilized and immunoblotted with anti-GPIb␤-P. Anti-GPIb␤-P antibody specifically reacted with a protein of molecular mass, 24 kDa, corresponding to GPIb␤ (Fig. 2B) , which is also immunoblotted by a previously characterized antibody specific for the C-terminal domain of GPIb␤ (anti-Ib␤C) (14) . Furthermore, preincubation of platelets with a specific PKA inhibitor, PKI, dramatically inhibited the reactivity of anti-GPIb␤-P with GPIb␤. In contrast, treatment of platelets with the PKA activator, forskolin, enhanced the binding of anti-GPIb␤-P to GPIb␤ (Fig. 2B ). These results demonstrate that anti-GPIb␤-P specifically recognizes GPIb␤ only when Ser 166 is phosphorylated. To determine whether GPIb␤ expressed in CHO cells was phosphorylated, and whether the above described mutants of GPIb-IX are phosphorylation-deficient, the lysates from wild type and mutant GPIb-IX-expressing cells were immunoblotted with anti-GPIb␤-P. Fig 2C shows that anti-GPIb␤-P reacted with the wild type GPIb␤ expressed in 1b9 cells but failed to react with GPIb␤ from the S166A or ⌬165 mutant cells. Thus, wild type GPIb␤ expressed in CHO cells is phosphorylated at Ser 166 , but the S166A and the ⌬165 mutants are phosphorylation-deficient at Ser 166 . These data also further demonstrate that anti-GPIb␤-P antibody is specific for phosphorylated Ser 166 .
VWF Binding to GPIb-IX Is Regulated through GPIb␤ Phosphorylation-To examine whether phosphorylation at Ser
166 of GPIb␤ plays a role in regulating the VWF-binding function of GPIb-IX, cells expressing wild type GPIb-IX (1b9) and the S166A mutant were incubated with increasing concentrations of soluble human VWF in the presence of ristocetin, a modulator that induces VWF binding to GPIb-IX. The S166A mutant demonstrated significantly increased VWF binding compared with 1b9 cells (Fig. 3A) . This increased VWF binding to the FIG. 1. Phosphorylation-deficient mutants of GPIb␤. The schematic illustrates the mutations made in the cytoplasmic domain of GPIb␤. The mutant ⌬165 is a truncation mutant lacking the C-terminal amino acids 166 -181 (including Ser 166 and the reported 14-3-3 binding site). The S166A mutant is a conservative mutation changing Ser 166 to alanine, eliminating phosphorylation at this site.
FIG. 2. Specific binding of anti-GPIb␤-P to phosphorylated Ser
166 peptide corresponding to the C-terminal sequence of GPIb␤. A, the synthetic phosphopeptide, CRAAARLpSLTDPLV, or equivalent nonphosphorylated peptide, CRAAARLSLTDPLV, were conjugated to BSA and dot blotted onto nitrocellulose. As a control, BSA was also applied to the nitrocellulose membrane. Purified anti-GPIb␤-P antibody was incubated with the nitrocellulose for 2 h at 22°C. After further incubation with horseradish peroxidase-conjugated goat antirabbit IgG, bound antibody was detected using enhanced chemiluminescence. Note that the anti-GPIb␤-P antibody specifically recognized the phosphorylated peptide but not the nonphosphorylated peptide nor BSA. B, washed resting platelets were incubated with Me 2 SO (0.05%, Control), membrane-permeable PKI (100 M), or forskolin (2 M) for 1 h at 37°C then solubilized as described under "Materials and Methods." The lysates were immunoblotted using the anti-GPIb␤-P antibody (left panel) or the anti-Ib␤C antiserum (14) (right panel) directed against the nonphosphorylated GPIb␤ C-terminal sequence. C, CHO cells expressing wild type GPIb-IX (1b9), the GPIb␤ C-terminal domain deletion mutant ⌬165, and the Ser 166 to Ala point mutant (S166A) were resuspended in modified Tyrode's buffer and then solubilized as described under "Materials and Methods." The lysate was immunoblotted with the anti-GPIb␤-P antibody. S166A mutant was not caused by differences in GPIb-IX expression level, as the expression levels of the two cell lines were comparable (Fig. 3B) . Furthermore, the VWF binding data shown in Fig. 3A was corrected relative to the ratio of the expression levels between the two cell lines. Thus, the mutant S166A showed an increased VWF-binding function. We also examined VWF binding to cells expressing the ⌬165 mutant (⌬165). The ⌬165 mutant, lacking the C-terminal cytoplasmic residues 166 -181 of GPIb␤, also showed an increase in ristocetin-induced VWF binding in a manner that is similar to the S166A mutant (Fig. 4) . Thus, disruption of Ser 166 phosphorylation in GPIb␤ or deletion of the phosphorylation site of GPIb␤ enhanced the VWF-binding function of GPIb-IX.
In platelets, GPIb␤ is phosphorylated by PKA (20, 21) . To determine whether PKA in CHO cells is also responsible for phosphorylation of GPIb␤ and the negative regulation of VWFbinding function, we examined the effects of a specific PKA inhibitor, PKI, on GPIb␤ phosphorylation and on VWF-binding function of GPIb-IX in CHO cells expressing wild type GPIb-IX (1b9). Fig. 5A shows that the phosphorylation level of wild type GPIb␤ is reduced by PKI treatment. Coincident with the reduced GPIb␤ phosphorylation, VWF binding to 1b9 cells was enhanced by PKI treatment (Fig. 5B) , in a manner similar to the increased VWF binding in the S116A mutant lacking the PKA-phosphorylation site of GPIb␤ (Fig. 5C) . The increased VWF binding to the S166A mutant, however, was not inhibited by the PKA activator forskolin (Fig. 5C ). Taken together, these data indicate that VWF-binding function of GPIb-IX is negatively regulated by PKA-mediated phosphorylation of GPIb␤ in this CHO cell model.
Effects of Ser 166 -deficient Mutations on Cell Adhesion to VWF under
Flow-GPIb-IX binding to VWF mediates transient adhesion (or rolling) of platelets on subendothelial-bound VWF under flow conditions. We therefore examined whether the ⌬165 and S166A mutants of GPIb-IX also affect GPIb-IX-dependent cell adhesion to VWF under flow conditions. As controls, we also examined adhesion of these cell lines to BSAcoated surfaces. No cells from the mutant GPIb-IX-expressing cell lines or from the wild type GPIb-IX cell line adhered to BSA-coated surface at shear rates above 1080 s Ϫ1 . As reported previously, wild type GPIb-IX-expressing cells adhered poorly on a VWF-coated surface. At a shear rate of 1080 s Ϫ1 or higher, no 1b9 cells were seen to roll on the VWF-coated surface (Fig.  6 ). In contrast, both the S166A and ⌬165 mutant cells showed transient adhesion on the VWF-coated surface (Fig. 6) . Interestingly, the truncation mutant ⌬165 showed a greater increase in adhesion compared with the S166A mutant at 1080 s Ϫ1 shear rate. Although the reason for this difference remains to be investigated, it may be relevant that the ⌬165 mutant not only lacks the phosphorylation site at Ser 166 but also lacks the entire C-terminal domain containing the reported 14-3-3 binding site in GPIb␤. Thus, phosphorylation at Ser 166 of GPIb␤ negatively regulates cell adhesion and rolling on immobilized VWF under flow conditions, and in addition to Ser 166 phosphorylation, the C-terminal domain of GPIb␤ containing the previously reported 14-3-3 binding site may also be important in negatively regulating GPIb-IX function.
Negative Regulation of VWF Binding to GPIb-IX by PKAmediated Phosphorylation in Human Platelets-We showed above that the VWF-binding function of GPIb-IX is negatively regulated by PKA-dependent GPIb-IX phosphorylation at Ser 166 in CHO cells. To verify whether PKA also negatively regulates the VWF-binding function of GPIb-IX in platelets, platelets were preincubated with PKI or forskolin and then FIG. 3 . VWF binding to the S166A mutant of GPIb-IX. A, CHO cells expressing wild type GPIb-IX (1b9) or the GPIb␤ mutant S166A (Ser to Ala mutation) were incubated in the presence of 1.25 mg/ml ristocetin and an increasing concentration of purified human VWF at 22°C for 30 min. Bound VWF was detected using a FITC-labeled anti-VWF monoclonal antibody (SZ29) and analyzed by flow cytometry as described under "Materials and Methods." The fluorescence intensity (geomean) of VWF binding was corrected for the ratio of the GPIb-IX expression levels between the two cell lines as determined in B. Shown in the figure are data from three separate experiments (mean Ϯ S.D.). B, the surface expression levels of GPIb-IX on CHO cells expressing wild type GPIb-IX (1b9) and the S166A mutant were analyzed by flow cytometry after incubation with 20 g/ml of the anti-GPIb␣ monoclonal antibody SZ2 followed by FITC-labeled goat anti-mouse IgG antibody.
FIG. 4. VWF-binding to ⌬165 mutant of GPIb-IX.
CHO cells expressing wild type GPIb-IX (1b9) and mutant ⌬165 (lacking residues 166 -181) were incubated with 35 g/ml of human VWF in the presence of 1.25 mg/ml ristocetin or with ristocetin alone. VWF binding was detected with the FITC-labeled anti-VWF monoclonal antibody, SZ29, and analyzed by flow cytometry. The cells were also analyzed for surface expression of GPIb-IX using an anti-GPIb␣ (SZ2) monoclonal antibody followed by a FITC-labeled goat anti-mouse antibody and analyzed by flow cytometry. The fluorescence intensity (geomean) of VWF binding was corrected for the ratio of the GPIb-IX expression levels between the two cell lines (1b9/⌬165 ϭ 1/1.37). Shown in the figure are the results from 3 separate experiments (mean Ϯ S.D.).
allowed to bind soluble VWF in the presence of botrocetin. The integrin inhibitor, RGDS, was added to all reactions to exclude any role of integrin ␣ IIb ␤ 3 in VWF binding. Treatment of platelets with PKI significantly increased VWF binding to platelets compared with control untreated platelets (Fig. 7A) . This increase was not due to the activation of the integrin ␣ IIb ␤ 3 because the platelets were preincubated with the integrin inhibitor, RGDS. On the other hand, incubation with forskolin induced a decrease in VWF binding (Fig. 7A) . When the platelets were preincubated with PKI and then incubated with forskolin, PKI was able to reverse the inhibitory effects of forskolin (Fig. 7B) . Furthermore, to examine if PKA negatively regulates GPIb-IX-mediated agglutination, PRP was preincubated with PKI in the presence or absence of forskolin. Platelet agglutination was induced by the addition of ristocetin in the presence of the integrin inhibitor, RGDS. Incubation of PRP with forskolin induced a decrease in GPIb-IX-mediated agglutination (Fig. 7C) . When PRP was preincubated with PKI prior to addition of forskolin, the inhibitory effects of forskolin on ristocetin-induced platelet agglutination was reversed (Fig.  7C) , indicating that PKA negatively regulates GPIb-IXdependent platelet agglutination. In parallel with their effects on VWF binding, PKI induced a significant decrease in the phosphorylation of GPIb␤ at Ser 166 , and forskolin induced a significant increase in GPIb␤ phosphorylation (Fig. 7D) . These data are consistent with PKA-induced phosphorylation of GPIb␤ negatively regulating GPIb-IX-VWF interaction.
Stoichiometry of GPIb␤ Phosphorylation in CHO Cells and in Platelets-
We showed previously (38) and also here (Figs. 3 and  6 ) that wild type GPIb-IX expressed in CHO cells poorly bound VWF and poorly adhered to a VWF-coated surface under both static and flow conditions. In contrast, resting platelets bind VWF in the presence of ristocetin (Fig. 7) and adhere to VWF under high shear rate flow conditions (39) . The regulatory mechanism causing this difference in the receptor function of GPIb-IX between CHO cells and platelets has never been satisfactorily explained. As we show here, the VWF-binding function of GPIb-IX is negatively regulated by PKA-mediated phosphorylation of GPIb␤ at Ser 166 and enhanced in Ser , solubilized, and then immunoblotted with the anti-GPIb␤-P antibody to detect GPIb␤ phosphorylation at Ser 166 or with the anti-Ib␤C antibody to detect total GPIb␤. The relative quantity of phosphorylated GPIb␤ in 1b9 cells was determined by scanning the protein bands and analyzing band density using NIH Image (mean Ϯ S.D., n ϭ 3). The results are expressed as percent change from the control. B, 1b9 cells were preincubated without or with 50 M PKI for 15 min at 22°C then allowed to bind VWF (35 g/ml) in the presence of ristocetin (1.25 mg/ml). As a negative control, cells were incubated with ristocetin alone in the absence of VWF. VWF binding was detected using the anti-VWF antibody SZ29 by flow cytometry as described under "Materials and Methods." Note that PKI treatment enhanced VWF binding. C, S166A cells were pre-incubated with 2 M forskolin or 0.2% Me 2 SO (vehicle) for 5 min at 22°C then allowed to incubate with ristocetin in the absence (Control) or presence of VWF. Binding of VWF was detected by flow cytometry as described in B.
FIG. 6. Effects of GPIb␤ mutations on
GPIb-IX-dependent transient cell adhesion to VWF under flow conditions. Wild type GPIb-IX-expressing cells (1b9) and GPIb␤ mutant cells, S166A and ⌬165, were perfused into a VWF-coated parallel plate flow chamber at the indicated shear rates as described under "Materials and Methods." Transient adhesion (rolling) of these cells was recorded using a videotape recorder. The number of rolling cells was counted in randomly selected fields of 0.18 mm 2 . Each field was evaluated for 10 s. The results shown are the mean Ϯ S.D. of cell counts/mm 2 (n ϭ 10). Statistical analysis revealed that the difference between 1b9 cells and the two mutant cell lines are significant (p Ͻ 0.01 in both cases). These cell lines were also perfused into BSA-coated parallel plate flow chamber. Transient adherent cells on BSA-coated surface are zero for all of three cell lines.
7D, treatment of washed platelets with forskolin, a PKA activator, increased the reactivity of anti-GPIb␤-P by about 100% in immunoblots, suggesting that a significant proportion (ϳ50%) of GPIb␤ in resting platelets is dephosphorylated at Ser 166 (Fig. 7) , a result consistent with previously published data (27) . In contrast, forskolin failed to significantly enhance the reactivity of anti-GPIb␤-P with GPIb-IX expressed in CHO cells (Fig. 5) , indicating that GPIb␤ phosphorylation is near maximal levels. To further compare the Ser 166 phosphorylation between platelets and 1b9 cells, platelets or 1b9 cells were solubilized, and GPIb-IX in the cell lysate was immunoprecipitated repeatedly with anti-GPIb␤-P to deplete phosphorylated GPIb␤. The phosphorylated GPIb-IX complex immunoprecipitated with anti-GPIb␤-P and the depleted cell lysates were then analyzed by SDS-PAGE and immunoblotted with a monoclonal antibody against the extracellular domain of GPIb, SZ-2. In CHO cells, following repeated immuno-depletion with antiGPIb␤-P, no GPIb was detected in the cell lysates, suggesting that almost all GPIb-IX molecules expressed in CHO cells are in the Ser 166 -phosphorylated form (Fig. 8B) . In contrast, ϳ35%
of the GPIb remained in the platelet lysate following antiGPIb␤-P depletion (Fig. 8A ). These results demonstrate that there are two populations of GPIb␤ in platelets, a Ser 166 -phosphorylated form and a Ser 166 -dephosphorylated form, and that all GPIb-IX molecules expressed in CHO cells are phosphorylated at Ser 166 of GPIb␤. This explains why GPIb-IX in platelets shows higher VWF binding and adhesion function than GPIb-IX expressed in CHO cells, and suggests that dynamic regulation of phosphorylation levels of GPIb␤ in platelets may be a mechanism to regulate platelet adhesion to VWF.
DISCUSSION
It has been shown previously (19 -21) that the cytoplasmic domain of GPIb␤ is phosphorylated at Ser 166 . It is not clear, however, how, and if, phosphorylation at Ser 166 affects GPIb-IX function. In this study, we conclude that GPIb-IX with GPIb␤ phosphorylated at Ser 166 is in a resting form and poorly interacts with VWF and that dephosphorylation at Ser 166 up-regulates the VWF-binding function of GPIb-IX. These conclusions are supported by the finding that GPIb-IX expressed in CHO cells is nearly 100% phosphorylated at Ser 166 and poorly binds to VWF and that the conserved point mutation changing Ser 166 to alanine to abolish Ser 166 phosphorylation significantly enhances the VWF-binding function of GPIb-IX. Furthermore, we show that the PKA activator, forskolin, increases GPIb␤ phosphorylation in platelets but reduces VWF binding. In contrast, the PKA inhibitor, PKI, inhibited GPIb␤ phosphorylation in both CHO cells and platelets and enhanced ristocetin-induced VWF binding. Thus, our data indicate that PKA-mediated phosphorylation of GPIb␤ at Ser 166 negatively regulates VWF binding to GPIb-IX. This provides a novel intracellular signaling mechanism for regulation of the VWF-binding function of GPIb-IX and for PKA-mediated platelet inhibition.
Our finding that VWF-binding function of GPIb-IX is nega-
PKA-mediated phosphorylation of GPIb␤ negatively regulates VWF binding to GPIb-IX in platelets. A, washed resting platelets (1.0 ϫ 10 9 cells/ml) in modified Tyrode's buffer were preincubated without or with 100 M PKI (PKI ϩ VWF) for 15 min, 2 M forskolin (forskolin ϩ VWF), or 0.1% Me 2 SO (VWF) for 10 min at 22°C and then incubated with VWF (35 g/ml) in the presence of botrocetin (5 g/ml). VWF binding was analyzed as described under "Materials and Methods." B, washed resting platelets in modified Tyrode's buffer were treated without (forskolin ϩ VWF) or with 100 M PKI (PKI ϩ forskolin ϩ VWF) for 15 min at 22°C and then incubated with 2 M of forskolin for 10 min at 22°C. The cells were then incubated with or without VWF (botrocetin) in the presence of botrocetin, stained with FITC-labeled SZ29, and analyzed using flow cytometry. C, PRP was first treated with the integrin inhibitor RGDS. The RGDS-treated PRP was then preincubated without or with 100 M PKI for 10 min and then incubated with 2 M forskolin or 0.05% Me 2 SO for 5 min at 22°C. Ristocetin (1.25 mg/ml) was then added to induce GPIb-IX-mediated agglutination, which was recorded using a platelet turbidometric aggregometer at 37°C. D, washed resting platelets in Tyrode's buffer (1.0 ϫ 10 9 cells/ml) were treated with 100 M PKI or 2 M forskolin for 1 h at 37°C. Platelets were solubilized as described under "Materials and Methods." The platelet lysate was immunoblotted using the antiGPIb␤-P antibody to detect phosphorylated GPIb␤, or using the antiGPIb␤ antibody to monitor the level of total GPIb␤. Levels of phosphorylated GPIb␤ in platelets were quantitated by scanning the protein bands and analyzing band density using NIH Image (mean Ϯ S.D., n ϭ 4). The results are shown as percent changes from the control. Slight loading errors between different samples were corrected using the ratio of the total amount of GPIb␤ between samples.
FIG. 8.
The stoichiometry of GPIb␤ phosphorylation in resting platelets and 1b9 cells. Platelets (A) and 1b9 cells (B) were solubilized as described under "Materials and Methods," GPIb␤ phosphorylated at Ser 166 in the lysates was immunoprecipated repeatedly using antiGPIb␤-P (GPIb␤-P) or rabbit IgG antibody to depletion. The immunoprecipitated, phosphorylated GPIb-IX proteins (P) and the lysates (S) were immunoblotted with the anti-GPIb␣ monoclonal antibody SZ2 to detect GPIb-IX level. Note that GPIb-IX in 1b9 cells was almost totally depleted by the anti-GPIb␤-P antibody, whereas GPIb-IX in the platelets was only partially immunoprecipitated by anti-GPIb␤-P.
tively regulated by PKA-dependent phosphorylation of Ser 166 of GPIb␤ is physiologically and pathologically relevant. It is currently believed that GPIb-IX in normal circulating platelets does not bind to soluble VWF. At the site of vascular injury, VWF binding to GPIb-IX occurs when GPIb-IX is exposed to subendothelial-bound VWF. Interaction of VWF with the subendothelium is thought to induce a conformational change in VWF and thus allow its interaction with GPIb-IX. In vitro, this change in VWF is mimicked by surface immobilization of VWF or by the VWF modulators, ristocetin or botrocetin. However, recent studies show that in thrombotic microangioapathy (TMA) including thrombotic thrombocytopenic purpura (TTP), unusually large VWF multimers in the circulation interact with circulating platelets to cause microthrombosis and thrombocytopenia (40, 41) . These unusually large VWF multimers are caused by a deficiency in the VWF-cleaving metalloprotease, ADAMTS13. Thus, unusually large VWF multimers appear to be able to interact with circulating platelets in these patients. Interestingly, although ADAMTS13 is deficient or decreased in many classic TTP patients, it is normal in patients with bone marrow transplant-associated TTP and several other types of thrombotic microangioapathy (40, 42) , suggesting that additional mechanisms may be responsible for the increased interaction of large VWF multimers with platelets in these patients. Also, as ADAMTS13 protease levels fluctuate under different physiological and pathological conditions (41) , and as hemostatically active large VWF multimers are present in normal individuals, it appears that a regulatory mechanism that controls the interaction between circulating large VWF multimers and platelets would be necessary to prevent the TTPlike thrombotic and hemostatic disorders in normal circulation. In this respect, although it has been thought that the ligandbinding function of GPIb-IX is not regulated in platelets, we have recently found that intracellular changes in GPIb-IX such as cytoskeletal association may affect the VWF-binding functions of GPIb-IX (38) . In this study, we show that the VWFbinding function of GPIb-IX is regulated in addition by the PKA-mediated phosphorylation of GPIb␤ at Ser 166 , indicating that VWF binding to GPIb-IX is not only controlled by VWF conformation but is also regulated by the cAMP-mediated intracellular signal. This dual regulation of ligand-receptor interaction may reflect the requirement to tightly control the VWF-binding function of GPIb-IX to prevent TTP-like disorders in the normal circulation.
It is not clear how phosphorylation of GPIb␤ regulates the ligand-binding function of GPIb-IX. There are several possible mechanisms. First, Ser 166 is a key residue in a 14-3-3 binding motif, and phosphorylation at Ser 166 has been reported to upregulate 14-3-3 binding to the 14-3-3 binding sequence in GPIb␤ (17, 18) . Interestingly, a truncation mutation of GPIb␤ that lacked the C-terminal 16 residues including the 14-3-3 binding site showed similarly enhanced VWF binding and showed an enhanced transient cell adhesion compared with wild type GPIb-IX-expressing cells (Figs. 4 and 6 ). This suggests that this region of GPIb␤ is important in the negative regulation of GPIb-IX-dependent cell adhesion to the immobilized VWF. It is therefore possible that the interaction of 14-3-3 with the cytoplasmic domain of GPIb␤ may be important in negatively regulating GPIb-IX interaction with VWF, and thus up-regulation of 14-3-3 interaction by Ser 166 phosphorylation would also negatively regulate VWF-binding function. Secondly, it is possible that phosphorylation at Ser 166 directly or indirectly induces a conformational change in the extracellular ligand-binding domain of GPIb␣. This possibility is consistent with a recent report that an anti-GPIb␤ monoclonal antibody causes inhibition of the ligand-binding function of GPIb-IX (43) . Thirdly, as we showed previously that association between GPIb-IX and the membrane skeleton regulates ligandbinding function (38) , it is also possible that phosphorylation of GPIb␤ induces reorganization of the GPIb-IX-associated membrane skeleton, which in turn regulates the VWF-binding function of GPIb-IX. Consistent with this hypothesis, it has been shown previously by Fox and Berndt (27) that phosphorylation of GPIb␤ is associated with inhibition of actin polymerization during platelet activation, which may involve the reorganization of GPIb-IX-associated membrane skeletal structure.
The CHO cell model has been extensively used to study the structure and function of GPIb-IX. However, as we showed previously (38) and here, GPIb-IX-expressing CHO cells adhere poorly to human VWF under flow conditions. Our data is consistent with the findings of Cunningham et al. (12) and Cranmer et al. (44) who also showed that CHO cells expressing wild type GPIb-IX adhered poorly to human VWF-coated surfaces under static conditions (in the absence of botrocetin) and rolled poorly on human VWF under high shear rate flow conditions (44) . However, a more recent paper by Williamson et al. (45) reported an apparent contradiction between their data and ours as it showed significant adhesion of wild type GPIb-IXexpressing CHO cells to bovine VWF. However, there are two major differences between Williamson's and our studies (and the results of Crammer et al. using human VWF (44)). Williamson et al. (45) examined the interaction of GPIb-IX-expressing cells with bovine VWF, which is similar to the result of Cranmer et al. using bovine VWF (44) . In contrast, we (38) and Cranmer et al. (44) showed that wild type GPIb-IX-expressing cells adhere poorly to immobilized human VWF under high shear rate (and static) conditions. It is known that bovine VWF is different from human VWF in that it can bind to human platelet GPIb-IX without requiring any VWF modulation (such as immobilization or ristocetin) (46, 47) . This suggests that binding of bovine VWF to human platelets may not be regulated by the physiological regulatory mechanisms relevant to the interaction of human platelets with human VWF (2) . There is also a major difference in our flow adhesion assays and those of Williamson et al. (45) . In the assay of Williamson et al. (45) , GPIb-IX-expressing CHO cells were allowed to interact with the VWF-coated surface under static conditions or at a very low flow rate for 5 min to initiate cell adhesion. The shear rate was then increased, thus in reality reflecting the shear resistance of statically adherent cells. In our assay system, cells flow across the VWF-coated surface at constant high shear rates, which mimics the platelet adhesion process in blood vessels. Under these flow conditions, CHO cells expressing wild type GPIb-IX adhere poorly to VWF. We show that phoshorylation of GPIb␤ at Ser 166 is associated with inhibition of VWF-binding function of GPIb-IX. We also show that almost all wild type GPIb-IX molecules expressed in CHO cells are phosphorylated at Ser 166 . These data suggest that PKA-dependent phosphorylation at Ser 166 of GPIb␤ may contribute to the poor VWF-binding function of GPIb-IX in CHO cells. In contrast to CHO cells, phosphorylation of Ser 166 in human platelets is dynamically regulated (Figs. 7 and 8 ) (27) , and a significant percentage (30 -50%) of GPIb-IX molecules in platelets is dephosphorylated at Ser 166 . Correlated with the presence of dephosphorylated forms of GPIb-IX, ristocetin-induced VWF binding to GPIb-IX is significantly higher in platelets. VWF-binding function of GPIb-IX is also retained in fixed platelets, suggesting that at least a portion of GPIb-IX molecules expressed on platelet surface are in an active state. We show that inhibition of PKA significantly further enhances VWF binding to platelets (Fig. 7) , which is associated with dephosphorylation of GPIb␤. Thus, we speculate that one of the possible mechanisms by which agonists
